AusCann develops capsule cannabinoid medicine

Company News

by Rachael Jones

Pharmaceutical company AusCann Group Holdings (ASX:AC8) has successfully completed a pilot study for its final dose form for its cannabinoid medicines.

The study was carried out over the last ten months to be ready for the release of AusCanns’ first cannabiniond medicines in the first half of 2019.

The oral delivery dose form has been developed as a solid capsule and a patent has been lodged.

Shares in AusCann Group Holdings (ASX:AC8) is trading 12.88 per cent higher to 92c

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.